Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

IWP-2

IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ[1][2].

Product Specifications

CAS Number

686770-61-6

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Casein Kinase; Porcupine; Wnt

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/IWP-2.html

Purity

99.93

Solubility

DMF : 12.5 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 2 mg/mL (ultrasonic)

Smiles

O=C(NC1=NC2=CC=C(C)C=C2S1)CSC3=NC(CCS4)=C4C(N3C5=CC=CC=C5)=O

Molecular Formula

C22H18N4O2S3

Molecular Weight

466.60

Precautions

H302, H315, H319, H335

References & Citations

[1]Chen B, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009 Feb;5 (2) :100-7.|[2]Maiti G, et al. The Wingless homolog Wnt5a stimulates phagocytosis but not bacterial killing. Proc Natl Acad Sci U S A. 2012 Oct 9;109 (41) :16600-5.|[3]García-Reyes B, et al. Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) δ/ε. J Med Chem. 2018 May 10;61 (9) :4087-4102.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

CK1

Citation 01

ACS Comb Sci. 2019 Dec 9;21 (12) :805-816.|Adv Mater. 2021 Dec;33 (49) :e2104829.|Autoimmunity. 2023 Dec;56 (1) :2182741.|Biocell. 2025 Feb 28.|Biochem Pharmacol. 2019 Nov;169:113608.|Bioengineering (Basel) . 2023 Jun 9;10 (6) :702.|bioRxiv. 2024 Mar 13.|Cell Rep Methods. 2024 May 8:100777.|Clin Sci. 2023 Jan 13;137 (1) :109-127.|Dev Cell. 2020 Dec 21;55 (6) :679-694.e11.|eNeuro. 2025 Jan 9:ENEURO.0347-24.2024.|Exp Cell Res. 2022 Nov 11;422 (1) :113416.|Exp Ther Med. 2020 Mar;19 (3) :1701-1710.|J Appl Polym Sci. 2024 Sep 25.|J Cell Physiol. 2020 Jul;235 (7-8) :5811-5822.|J Inflamm Res. 2024 Nov 19:17:8945-8964.|Microb Pathog. 2024 Sep 21:106960.|Neoplasia. 2024 Dec 30:60:101096.|Patent. US20180263995A1.|PLoS One. 2024 Jan 5;19 (1) :e0287206.|SSRN. 2024 Mar 26.|Stem Cell Res Ther. 2024 Oct 8;15 (1) :350.|Stem Cells Transl Med. 2021 May;10 (5) :743-755.|Toxicon. 2026 Jan:269:108660.|Nat Protoc. 2024 Jul;19 (7) :1911-1939.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

Recombinant PAK1 Antibody
RC-4521-01 50 μL

Recombinant PAK1 Antibody

Sign In for Pricing
View Details
Recombinant PAK1 Antibody
RC-4521-02 100 µL

Recombinant PAK1 Antibody

Sign In for Pricing
View Details
Recombinant PAK1 Antibody
RC-4521-03 1 mL

Recombinant PAK1 Antibody

Sign In for Pricing
View Details
1,2-Dehydro Reticuline Iodide
TRC-D230065-50MG 50 mg

1,2-Dehydro Reticuline Iodide

Sign In for Pricing
View Details
PNPLA8 Rabbit Polyclonal Antibody
TA392840 100 µL

PNPLA8 Rabbit Polyclonal Antibody

Sign In for Pricing
View Details
Venetoclax Piperazinyl Oxy Impurity
TRC-V341770-25MG 25 mg

Venetoclax Piperazinyl Oxy Impurity

Sign In for Pricing
View Details